Monitor the execution of cost reduction initiatives ($2.5M annualized EBITDA savings expected) and track OEM Channel pricing stabilization. The CFO transition could create near-term uncertainty, but the reaffirmed guidance and commercial momentum suggest management confidence in 2026 recovery.
ANIK drugs
ANIK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 26 $12.79entry
- T+1 · 9mo ago +12.28%α +12.73% · $14.36
- T+5 · 9mo ago +11.42%α +12.54% · $14.25
- T+20 · 8mo ago +15.32%α +21.73% · $14.75
- T+60 · 6mo ago +17.44%α +9.69% · $15.02
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Anika Therapeutics reported flat Q4 revenue of $30.6M but full-year 2025 revenue declined 6% to $112.8M, driven by a 17% drop in OEM Channel sales. The company reaffirmed 2026 revenue guidance of $114-122.5M and announced CFO David Colleran's planned departure in May 2026. Despite improved gross margins and strong commercial channel growth, the negative revenue trend and executive departure outweigh positive operational improvements.
Key Financial Metrics
Key Facts
- Q4 2025 revenue: $30.6M (flat YoY), full-year 2025 revenue: $112.8M (down 6% YoY)
- Commercial Channel revenue grew 22% in Q4 and 15% for full year 2025
- OEM Channel revenue declined 12% in Q4 and 17% for full year 2025 due to U.S. pricing pressures
- CFO David Colleran will depart in May 2026 after transition period
- Company reaffirmed 2026 revenue guidance of $114-122.5M (up 1-9% YoY)
- Generated $11.2M operating cash flow and $4.4M free cash flow for full year 2025
Financial Impact
Full-year revenue down $7.1M YoY, with $13.4M decline in OEM Channel partially offset by $6.3M increase in Commercial Channel
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Commercial Channel | $48.4M | +15.0% |
| OEM Channel | $64.4M | -17.0% |
Risk Factors
- Continued pricing pressure in U.S. OA Pain Management segment
- Leadership transition risk with CFO departure
- FDA approval timeline uncertainty for Hyalofast PMA and Cingal NDA
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-073401 |
| Document: d106406dex101.htm | 0001193125-26-073401 |
| Document: d106406d8k.htm | 0001193125-26-073401 |
| Document: 0001193125-26-073401-index-headers.html | 0001193125-26-073401 |
| Document: 0001193125-26-073401-index.html | 0001193125-26-073401 |
| Document: 0001193125-26-073401.txt | 0001193125-26-073401 |
Track record
13 reports on ANIK
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 6, 202610d ago 8-K Mixed 6/10 Entry $14.55 Now $12.92 −11.20% settles Feb 4
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $21.42 Now $12.92 −39.68% settles Jan 21
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $16.17 to $21.09 Now $12.92 −20.10% ▲ +30.43% +25.70% vs SPY
- Jul 14, 202617w ago 8-K Neutral 3/10 Entry $15.93 to $19.23 Now $12.92 −18.90% ▲ +20.72% +18.18% vs SPY
- Jun 23, 202620w ago 8-K Neutral 4/10 Entry $14.73 to $21.03 Now $12.92 −12.29% ▲ +42.77% +39.93% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 4/10 Entry $14.72 to $21.04 Now $12.92 +12.23% ▼ −42.93% −39.67% vs SPY
- Jun 8, 202623w ago DEFA14A Neutral 4/10 Entry $14.60 to $21.11 Now $12.92 −11.51% ▲ +44.59% +41.54% vs SPY
- Jun 1, 202624w ago DEFA14A Neutral 3/10 Entry $14.63 to $21.40 Now $12.92 −11.69% ▲ +46.27% +45.04% vs SPY
- Apr 30, 202628w ago Insider Cluster Mixed 5/10 Entry $14.85 to $16.17 Now $12.92 −13.00% ▲ +8.89% +7.41% vs SPY
- Apr 29, 202628w ago 8-K Mixed 6/10 Entry $12.39 to $14.95 Now $12.92 +4.28% ▲ +20.66% +16.55% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers